• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

A First: FDA Approves Pembrolizumab for Tissue-Agnostic Indication

Article

The drug is now indicated for adult and pediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumors that lack suitable alternative treatments or that have progressed on treatment.

Following a review of data from 15 different cancer types, the FDA has granted accelerated approval to the programmed death 1 (PD-1) inhibitor pembrolizumab for adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that lack suitable alternative treatments or that have progressed on treatment. The indication also includes patients with colorectal cancer (CRC) that is MSI-H or dMMR and who have progressed on fluoropyrimidine, oxaliplatin, and irinotecan.

The data from 5 uncontrolled, multi-center, single-arm studies, included 149 patients with MSI-H or dMMR cancers—a majority (90) had CRC and the remaining 59 were diagnosed with one of 14 other cancers. Patients were treated with 200 mg pembrolizumab every 3 weeks, or 10 mg/kg every 2 weeks, for a maximum of 24 weeks, until unacceptable toxicity or progression was observed.

The objective response rate was 39.6% (95% CI, 31.7 to 47.9) and the minimum duration of response was 6 months in 78% of patients who responded to the PD-1 inhibitor. Further, 11 complete responses and 48 partial responses were documented.

Merck, which has developed the drug, is expected to conduct further studies to confirm the clinical benefit of pembrolizumab for this indication.

In the past month, pembrolizumab has received FDA approvals for several indications, including advanced or metastatic urothelial carcinoma and metastatic nonsquamous non-small cell lung cancer (NSCLC). It was one of the first immuno-oncology agents to be approved for melanoma and for non-small cell lung cancer.

Related Videos
Will Shapiro
Video 1 - "Diagnosing and Understanding the Pathogenesis of Bronchiectasis"
Video 4 - "Challenges in Autoantibody Screening for Type 1 Diabetes"
Jeff Stark, MD, vice president, head of medical immunology, UCB
Video 7 - "Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients"
Video 7 - "Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients"
Video 6 - "Community Partnership: Increasing Public Awareness of CVD"
Video 6 - "Community Partnership: Increasing Public Awareness of CVD"
Screenshot of Raajit Rampal, MD, PhD
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.